FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor
Source: kpvi.com
Shows High Potency News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Shows High Potency. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Shows High Potency Today - Breaking & Trending Today
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the...
Source: prnewswire.com
Targeting DLL-3 for a variety of potential lung cancer therapies
In this article, ACROBiosystems demonstrates how DLL-3 could become a potential target for a variety of lung cancer therapies.
Source: news-medical.net